Vidarabine
Vidarabine (adenine arabinoside, Ara-A) is a purine nucleoside analog that is phosphorylated intracellularly to vidarabine triphosphate, which inhibits viral DNA polymerases and DNA primase, blocking viral DNA replication with selectivity for herpes viruses. It was used topically for herpes simplex keratitis and systemically for herpes encephalitis and neonatal herpes, but has largely been replaced by acyclovir due to the latter's improved safety and efficacy profile. Its antiviral mechanism targeting viral DNA polymerase established the template for subsequent nucleoside analog antivirals.
분자량
267.2400 g/mol
LogP
-1.10
TPSA
140.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D 구조
Cite this structure
Embed this structure
SMILES
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
Molecular Formula
C10H13N5O4
HBD / HBA
4 / 8
회전 가능 결합
2
무거운 원자
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Vidarabine (adenine arabinoside, Ara-A) is a purine nucleoside analog that is phosphorylated intracellularly to vidarabine triphosphate, which inhibits viral DNA polymerases and DNA primase, blocking viral DNA replication with selectivity for herpes viruses. It was used topically for herpes simplex keratitis and systemically for herpes encephalitis and neonatal herpes, but has largely been replaced by acyclovir due to the latter's improved safety and efficacy profile. Its antiviral mechanism targeting viral DNA polymerase established the template for subsequent nucleoside analog antivirals.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Vidarabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1090. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 21704. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vidarabine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vidarabine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vidarabine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vidarabine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vidarabine"></drugfyi-drug>